Coronary angioplasty: Back to the future

Puel and Sigwart, in 1986, deployed the first coronary stent to act as a scaffold preventing vessel closure reducing the incidence of angiographic restenosis. The first stents were bare metal stents. The first drug-eluting stents to be approved were coated with paclitaxel or sirolimus. Since these s...

Full description

Bibliographic Details
Main Authors: Nilkanth Chandrakant Patil, Veena Nanjappa
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Journal of the Practice of Cardiovascular Sciences
Subjects:
Online Access:http://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=1;spage=44;epage=52;aulast=Patil
Description
Summary:Puel and Sigwart, in 1986, deployed the first coronary stent to act as a scaffold preventing vessel closure reducing the incidence of angiographic restenosis. The first stents were bare metal stents. The first drug-eluting stents to be approved were coated with paclitaxel or sirolimus. Since these stents came with a lot of promise but also with risk of thrombosis, the next step was biodegradable stents. These stents are expected to degrade into nontoxic byproducts. They came with a lot of fanfare but are now being viewed with caution because of initial poor results. We do not know what the future holds.
ISSN:2395-5414
2454-2830